Phathom Pharmaceuticals, Inc. (PHAT)Healthcare | Biotechnology | Florham Park, United States | NasdaqGS
7.09 USD
-0.41
(-5.533%) ⇩
(Oct. 16, 2026, 3:19 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:33 a.m. EDT
The investment case for Phathom is currently fractured by a severe disconnect between optimistic analyst targets and the harsh reality of the company's financial trajectory. While analysts project a mean price of $20.45 based on a breakeven timeline, the stock has already lost nearly 70% of its value over the last five years, reflecting a market that has priced in significant structural deterioration. The recent narrowing of losses and reaffirmed profitability timeline offer a glimmer of hope, but the balance sheet remains precarious with negative book value and burning cash, while the stock trades at a discount to its 200-day average, signaling lingering skepticism. Crucially, the options market is screaming caution; the heavy concentration of put open interest and the inverted volatility skew suggest that sophisticated traders are positioning for further downside, viewing the current price as vulnerable to execution risks or competitive pressures. Until the company demonstrates sustained revenue growth and a stabilized balance sheet that can support the lofty analyst targets, the risk-reward profile remains skewed toward the downside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.142762 |
| AutoETS | 0.142772 |
| AutoARIMA | 0.142772 |
| MSTL | 0.152647 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 54.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.106 |
| Excess Kurtosis | -1.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.062 |
| Market Cap | 573,183,104 |
| Forward P/E | 6.59 |
| Beta | 0.50 |
| Profit Margins | -41.34% |
| Website | https://www.phathompharma.com |
As of Oct. 10, 2026, 9:33 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across nearly all expirations, with deep out-of-the-money puts showing massive accumulation relative to calls. The implied volatility skew is inverted, with puts trading at a substantial premium compared to calls, indicating a market consensus that the probability of further decline outweighs the chance of a recovery. While some call volume exists at strikes above the current price, the sheer weight of put positioning suggests a 'bet against' strategy dominates the options flow.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4212963 |
| Address1 | 100 Campus Drive |
| Address2 | Suite 102 |
| All Time High | 64.54 |
| All Time Low | 2.21 |
| Ask | 8.96 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,466,180 |
| Average Daily Volume3 Month | 1,387,206 |
| Average Volume | 1,387,206 |
| Average Volume10Days | 1,466,180 |
| Beta | 0.502 |
| Bid | 5.33 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | -4.3 |
| City | Florham Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.085 |
| Current Ratio | 1.924 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.5699 |
| Day Low | 6.98 |
| Display Name | Phathom Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,412,800 |
| Earnings Call Timestamp Start | 1,785,412,800 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | -40,134,000 |
| Ebitda Margins | -0.16746001 |
| Enterprise To Ebitda | -24.326 |
| Enterprise To Revenue | 4.074 |
| Enterprise Value | 976,302,848 |
| Eps Current Year | -0.0298 |
| Eps Forward | 1.0758 |
| Eps Trailing Twelve Months | -1.26 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.1853 |
| Fifty Day Average Change | -1.1002998 |
| Fifty Day Average Change Percent | -0.13442388 |
| Fifty Two Week Change Percent | -42.12963 |
| Fifty Two Week High | 18.31 |
| Fifty Two Week High Change | -11.224999 |
| Fifty Two Week High Change Percent | -0.61305296 |
| Fifty Two Week Low | 6.52 |
| Fifty Two Week Low Change | 0.56500006 |
| Fifty Two Week Low Change Percent | 0.08665645 |
| Fifty Two Week Range | 6.52 - 18.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,572,010,200,000 |
| Float Shares | 65,071,842 |
| Forward Eps | 1.0758 |
| Forward P E | 6.585797 |
| Free Cashflow | -32,627,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 371 |
| Fullday Change | -0.41499996 |
| Fullday Change Percent | -5.533333 |
| Fullday Price | 7.085 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.82922995 |
| Gross Profits | 198,734,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04644 |
| Held Percent Institutions | 0.94431996 |
| Implied Shares Outstanding | 80,900,934 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. |
| Long Name | Phathom Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 573,183,104 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_613615658 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -99,072,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 565,497,528 |
| Number Of Analyst Opinions | 11 |
| Open | 7.51 |
| Operating Cashflow | -36,693,000 |
| Operating Margins | -0.053379998 |
| Overall Risk | 7 |
| Phone | 877 742 8466 |
| Previous Close | 7.5 |
| Price Eps Current Year | -237.75168 |
| Price Hint | 2 |
| Price To Book | -1.6476743 |
| Price To Sales Trailing12 Months | 2.3916311 |
| Profit Margins | -0.41338003 |
| Quick Ratio | 1.82 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.41499996 |
| Regular Market Change Percent | -5.533333 |
| Regular Market Day High | 7.5699 |
| Regular Market Day Low | 6.98 |
| Regular Market Day Range | 6.98 - 7.5699 |
| Regular Market Open | 7.51 |
| Regular Market Previous Close | 7.5 |
| Regular Market Price | 7.085 |
| Regular Market Time | 1,792,178,392 |
| Regular Market Volume | 683,553 |
| Return On Assets | -0.088 |
| Revenue Growth | 0.88 |
| Revenue Per Share | 3.062 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 80,900,934 |
| Shares Percent Shares Out | 0.125 |
| Shares Short | 10,109,151 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,823,977 |
| Short Name | Phathom Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.13149999 |
| Short Ratio | 8.0 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PHAT |
| Target High Price | 29.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 20.09091 |
| Target Median Price | 21.0 |
| Total Cash | 182,478,000 |
| Total Cash Per Share | 2.256 |
| Total Debt | 552,024,000 |
| Total Revenue | 239,662,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.962175 |
| Two Hundred Day Average Change | -3.8771753 |
| Two Hundred Day Average Change Percent | -0.35368666 |
| Type Disp | Equity |
| Volume | 683,553 |
| Website | https://www.phathompharma.com |
| Zip | 7,932 |